全球生命科学展望2023年
The underlying growth of the life sciences sector—pharmaceutical, biotech, and medtech—is strong at a combined
US$2.83T.1,2,3 While growth has recently remained strong through increased demand and throughout the pandemic response
(particularly with COVID-19 vaccines), we are seeing life sciences companies shifting their portfolio strategies with the hope
of continuing this growth trajectory by any combination of acquisitions, divestitures of assets deemed not core to growth;
investments in R&D and an accelerated embracing of digital; and data technologies which are finally beginning to scale in
their adoption. Significant challenges remain though, such as the increasingly competitive market, the changing and evolving
regulatory landscape, increasing pricing and reimbursement pressures, and growing demands from patients and health care
providers for more effective medications and experiences as they manage health and well-being. All of this also while in the
face of broader geopolitical and economic uncertainty.